New calculator aims to simplify insulin dosing in hospitals

NCT ID NCT06206525

Completed Symptom relief Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new insulin dosing calculator for adults with type 2 diabetes when they are admitted to the hospital. The goal was to see if the calculator helps control blood sugar without causing dangerously low levels. Thirty-eight participants received their initial insulin dose from the calculator, and their results were compared to standard care. The study focused on safety and blood sugar control during the first 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: insulin dosing calculator
What this could lead to: If it works, this could make it easier and safer for doctors to give the right insulin dose to hospitalized patients with type 2 diabetes.
What could go wrong: This is a small feasibility trial with only 38 participants, so results may not apply to all patients. The calculator might not reduce high blood sugar or could cause low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Harborview Medical Center

Seattle, Washington, 98104, United States
UW Medical Center - Montlake

Seattle, Washington, 98195, United States
UW Medical Center - Northwest

Seattle, Washington, 98133, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.